在非小细胞肺癌中Cinobufagin的Pyroptosis介导的抗瘤活性
Ying Chen1, Feng Hu2, Jiahuan Lu3
1Department of Radiation Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Clinical and experimental pharmacology & physiology
|July 24, 2025
概括
奇诺布法根通过诱导细胞灭绝,一种被编程细胞死亡途径,有效地向非小细胞肺癌 (NSCLC). 这种天然化合物显示出作为治疗剂的希望,增强抗瘤免疫力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 仍然是全球癌症死亡的主要原因.
- 对于NSCLC治疗,迫切需要具有新作用机制的向疗法.
- 炎症性细胞灭绝,一种被编程细胞死亡的亲炎症形式,正在成为一种潜在的抗癌策略.
研究的目的:
- 为了研究在NSCLC中奇诺布法根的治疗疗效.
- 阐明在NSCLC中由黄素诱导的热的分子机制.
- 为了评估瘤免疫微环境上的 cinobufagin 的影响.
主要方法:
- 在体外研究中使用NSCLC细胞系和正常的支气管上皮细胞治疗 cinobufagin.
- 细胞活力测试 (CCK-8),RNA测序,LDH释放测试,传输电子显微镜和西式斑点测试.
- 在裸体老鼠异种移植模型中进行体内疗效研究,分析瘤热的标记物和免疫细胞透 (CD8+ T 细胞,NK 细胞).
主要成果:
- 奇诺布法根对NSCLC细胞表现出选择性细胞毒性,对正常细胞的毒性最小.
- 通过RNA-seq识别了与火死相关的途径,功能测定证实了通过caspase-3/GSDME激活通过cinobufagin诱导的火死.
- 在体内,素降低了瘤体积,并显著增加了NK细胞透和活性.
结论:
- 奇诺布法根通过诱导卡斯帕-3/GSDME介导的灭,在NSCLC中发挥抗瘤作用.
- 奇诺布法根治疗调节免疫微环境,增强NK细胞活性.
- 这些发现支持青素作为NSCLC向热亡的潜在治疗剂.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
1.2K
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
